Currently, In NSCLC, especially of the non-squamous histology, predictive biomarkers recommended for testing by the NCCN profiling panel are EGFR, KRAS, and BRAF mutations; ALK, RET, and ROS1 gene rearrangements; MET alterations including MET exon 14 skipping mutations and MET amplifications; ERBB2 (HER2) mutations; and NTRK 1/2/3 gene fusions [2]. The gene discussed is ERBB2; the disease is non-small cell lung carcinoma.